Effects of Intravenous Dexmedetomidine on Sensory and Motor Block Characteristics in Adults Undergoing Infraumbilical Surgery Under Subarachnoid Block
DOI:
https://doi.org/10.25751/rspa.42745Keywords:
Anesthesia, Spinal, Dexmedetomidine/therapeutic use, Nerve BlockAbstract
Introduction: Subarachnoid block is enhanced by intrathecal administration of adjuvants (opioids, α2-agonists, etc.) with bupivacaine. A potent α2-agonist, dexmedetomidine, causes sedation and analgesia when administered intravenously. Its intrathecal use is not approved. This study was designed to evaluate the effects of intravenous dexmedetomidine on subarachnoid block (SAB).
Methods: Sixty patients of the American Society of Anesthesiologists grade 1-2, of either sex, aged 18–60 years, undergoing infraumbilical surgery under SAB were randomized into two groups, group-C receiving 50 mL normal saline and group-D receiving dexmedetomidine infusion (0.5 mcg/kg in 50 mL normal saline) over 15 minutes within two minutes of SAB. The onset and duration of sensory and motor blocks were measured. Heart rate (HR), systolic (SBP), diastolic (DBP), and mean arterial pressure (MAP) were taken preoperatively, at SAB, 2, 4, 6, 8, 10, 15, 20, 25, 30, 45, 60, 90, and 120 minutes after SAB. Intraoperative sedation was assessed pre-drug infusion (post-SAB) and 30 and 60 minutes after SAB. Postoperative pain and sedation were assessed at 1, 2, 4, 8, 12 and 24 hours.
Results: Group-D showed a faster onset of sensory block and longer sensory and motor block than group-C (p<0.05). The onset of motor block was comparable between the groups. Group-C showed higher HR, SBP, DBP, and MAP than group-D (p<0.05). Group-D had higher sedation scores and less postoperative pain than group-C (p<0.05).
Conclusion: Dexmedetomidine causes a faster onset of sensory block, prolonged sensory and motor blocks with stable hemodynamics, better sedation, and postoperative analgesia.
Downloads
References
1. Swain A, Nag DS, Sahu S, Samaddar DP. Adjuvants to local anesthetics: Current understanding and future trends. World J Clin Cases. 2017;5:307-23. doi: 10.12998/wjcc.v5.i8.307.
2. Scott-Warren VL, Sebastian J. Dexmedetomidine: its use in intensive care medicine and anesthesia. BJA Education. 2016; 16: 242-6.
3. Lee S. Dexmedetomidine: present and future directions. Korean J Anesthesiol. 2019;72:323-30. doi: 10.4097/kja.19259.
4. Li R, Qi F, Zhang J, Ji Y, Zhang D, Shen Z, Lei W. Antinociceptive effects of dexmedetomidine via spinal substance P and CGRP. Transl Neurosci. 2015;6:259-64. doi: 10.1515/tnsci-2015-0028.
5. Wang X, Liu N, Chen J, Xu Z, Wang F, Ding C. Effect of Intravenous Dexmedetomidine During General Anesthesia on Acute Postoperative Pain in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin J Pain. 2018;34:1180-91. doi: 10.1097/AJP.0000000000000630.
6. Sachdeva A, Jaswal S, Walia HS, Batra YK. Correlating the Depth of Sedation Between the Ramsay Sedation Scale and Bispectral Index Using Either Intravenous Midazolam or Intravenous Propofol in Elderly Patients Under Spinal Anaesthesia. Cureus. 2023;15:e50763. doi: 10.7759/cureus.50763.
7. Atisook R, Euasobhon P, Saengsanon A, Jensen MP. Validity and Utility of Four Pain Intensity Measures for Use in International Research. J Pain Res. 2021;14:1129-39. doi: 10.2147/JPR.S303305.
8. Reddy VS, Shaik NA, Donthu B, Reddy Sannala VK, Jangam V. Intravenous dexmedetomidine versus clonidine for prolongation of bupivacaine spinal anesthesia and analgesia: A randomized double-blind study. J Anaesthesiol Clin Pharmacol. 2013;29:342-7. doi: 10.4103/0970-9185.117101.
9. Kaya FN, Yavascaoglu B, Turker G, Yildirim A, Gurbet A, Mogol EB, et al. Intravenous dexmedetomidine, but not midazolam, prolongs bupivacaine spinal anesthesia. Can J Anaesth. 2010;57:39-45. doi: 10.1007/s12630-009-9231-6.
10. Kumari R, Kumar A, Kumar S, Singh R. Intravenous dexmedetomidine as an adjunct to subarachnoid block: A simple effective method of better perioperative efficacy. J Anaesthesiol Clin Pharmacol. 2017;33:203-8. doi: 10.4103/joacp.JOACP_367_15.
11. Bhirud PH, Chellam S, Mote MN, Toal PV. Effects of intravenous dexmedetomidine on spinal anesthesia and sedation – A comparison of two different maintenance infusions. J Anaesthesiol Clin Pharmacol. 2020;36:78-82. doi: 10.4103/joacp.JOACP_129_18.
12. Bharthi Sekar E, Vijayaraghavan U, Sadiqbasha A. Effect of Intravenous Dexmedetomidine on Spinal Anesthesia. Cureus. 2021;13: e15708. doi: 10.7759/cureus.15708.
13. Kavya UR, Laxmi S, Ramkumar V. Effect of intravenous dexmedetomidine administered as bolus or as bolus-plus-infusion on subarachnoid anesthesia with hyperbaric bupivacaine. J Anaesthesiol Clin Pharmacol. 2018;34:46-50. doi: 10.4103/joacp.JOACP_132_16.
14. Verghese T, Dixit N, John L, George R, Gopal S. Effect of intravenous dexmedetomidine on duration of spinal anesthesia with hyperbaric bupivacaine - A comparative study. Indian J Clin Anaesth. 2019;6:97-101.
15. Sahoo A, Seelan P, Dasari G, Penmatsa S. Comparison of effectiveness between two different doses of intravenous dexmedetomidine as adjuvant to subarachnoid block for sub umbilical surgeries. J Med Sci. 2023;92:e838. doi: 10.1038/s41598-021-88726-2.
16. Thakkar PD, Patel DR, Shah UD, Gupta S, Dudhani R, Mirchandani B. Effect of intravenous dexmedetomidine on characteristics of spinal anesthesia with hyperbaric bupivacaine: a prospective study. J Popul Therap Clin Pharmacol. 2024;31:890-5.
17. Huang YY, Chang KY. Sensory block level prediction of spinal anesthesia with 0.5% hyperbaric bupivacaine: a retrospective study. Sci Rep. 2021;11:9105.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Neha Dwivedi, Pratiti Choudhuri, Pavan Nayar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles are freely available to be read, downloaded and shared from the time of publication.
The RSPA reserves the right to commercialize the article as an integral part of the journal (in the preparation of reprints, for example). The author should accompany the submission letter with a declaration of copyright transfer for commercial purposes.
Articles are published under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC).
After publication in RSPA, authors are allowed to make their articles available in repositories of their home institutions, as long as they always mention where they were published.
